| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a method for increasing the stability of the purified proteins. <P>SOLUTION: There is provided a method for improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperone (ASSC) to increase the stability and efficiency of the protein being administered, wherein the purified protein is an enzyme and the active site-specific chaperone is a reversible competitive inhibitor of the enzyme. The enzyme is an enzyme associated with a lysosomal storage disorder, such as α-galactosidase A or β-glucocerebrosidase. The reversible competitive inhibitor is a compound selected from the group consisting of 1-deoxygalactonojirimycin, α-allo-homonojirimycin, α-galacto-homonojirimycin, α-1-C-butyl-deoxynojirimycin, calystegine A3, calystegine B2, N-methyl-calystegine A3, and N-methyl-calystegine B2. <P>COPYRIGHT: (C)2012,JPO&INPIT |
